Convalescent plasma for haematological patients with SARS-CoV-2 pneumonia and severe depletion of B-cell lymphocytes following anti-CD20 therapy: a single-centre experience and review of the literature

Convalescent plasma (CP) therapy might be effective in patients with haematological malignanciesand B-cell depletion. We report a single-centre experience of COVID-19 patients with non-Hodgkinlymphoma and absence of B-cells as a consequence of anti-CD20 therapy successfully treated withCP from Octob...

Full description

Saved in:
Bibliographic Details
Published in:The New microbiologica 2022-01, Vol.45 (1), p.62-72
Main Authors: Oliva, Alessandra, Cancelli, Francesca, Brogi, Andrea, Curtolo, Ambrogio, Savelloni, Giulia, Siccardi, Guido, Marcelli, Giulia, Mazzuti, Laura, Ricci, Paolo, Turriziani, Ombretta, Antonelli, Guido, Venditti, Mario, Mastroianni, Claudio M
Format: Article
Language:English
Subjects:
Antibodies, Viral - therapeutic use
CD20 antigen
COVID-19
COVID-19 - drug therapy
COVID-19 - therapy
Depletion
Hematology
Humans
Immunization, Passive
Literature reviews
Lymphocytes
Lymphocytes B
Lymphoma
Non-Hodgkin's lymphoma
Patients
Pneumonia
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Convalescent plasma (CP) therapy might be effective in patients with haematological malignanciesand B-cell depletion. We report a single-centre experience of COVID-19 patients with non-Hodgkinlymphoma and absence of B-cells as a consequence of anti-CD20 therapy successfully treated withCP from October 2020 to May 2021. CP was given in the presence of pneumonia with respiratoryfailure despite standard treatment and consisted of three infusions on an alternate-day basis. A reviewof the current literature on this topic was also performed. Six patients were identified (medianage 59.5 years (range 50-73)). The last anti-CD20 drug administration occurred 60 days before infection(range 0-360). CP was administered after a median of 51 days (range 9-120) from SARS-CoV-2diagnosis, with an early improvement in all but one subject. We suggest a possible clinical benefitof convalescent CP treatment in COVID-19 patients with haematological malignancies and B-celldepletion having persistent/recurrent pneumonia.
ISSN:1121-7138